Sanofi and GSK are scaling up the manufacturing of the antigen and adjuvant with the target of producing up to one billion doses in 2021
Data shows 100% concordance with results from Dartmouth-Hitchcock’s lab-based polymerase chain reaction (PCR) test method
A new prognostic tool developed by an international team led by CTI-Bath paves the way for personalized medicine for cancer patients
The new AI technology will learn from past CT scans of COVID-19 pneumonia patients, reducing the burden on doctors making diagnoses
Ready-to-use kit enables rapid adeno-associated virus (AAV) titer determinations during the manufacture of AAV vectors
Antigen test reliably and quickly triages people suspected of SARS-CoV-2, with results ready in 15 minutes, allowing informed treatment decisions
FoundationOne Liquid CDx analyzes more than 300 cancer-related genes and multiple genomic signatures to inform treatment decisions for all solid tumor cancers
Combining image analysis with structured reporting, the software aims to improve and accelerate the detection of the virus
Test delivers results in just 15 minutes with no instrumentation, using proven lateral flow technology with demonstrated sensitivity of 97.1% and specificity of 98.5%
The real-time PCR workflow has a capacity of up to 6,000 tests per day per system, and demonstrated 100% agreement with authorized nasopharyngeal assays
QIAseq SARS-CoV-2 Primer Panel converts viral RNA samples into libraries ready for sequencing, whereas QIAGEN Digital Insights solutions support COVID-19 drug, vaccine and epidemiology research
Syndromic testing will streamline respiratory infection diagnosis as COVID-19 pandemic collides with start of flu season
Across all populations, BNT162b2 administration was well tolerated with mild to moderate fever in fewer than 20% of the participants
Regeneron will distribute REGN-COV2 in the U.S. and Roche will be responsible for distribution outside the U.S.
The consortium aims to determine the dynamics, function and potential for therapeutic intervention of the RNA and protein structures of SARS-CoV-2
IgM assay has 95.51% positive predictive value even when disease incidence is only 3%
The new assays are designed to enable turnaround times for next-generation sequencing results of less than 24 hours
Used to empower clinicians to quickly prescribe treatment regimens for multidrug-resistant TB, the test could help fill a critical gap that is jeopardizing global TB targets
Connecting the scientific community with two new online content-packed events
Nirsevimab is the first potential passive immunisation for infants to demonstrate sustained protection across the entire RSV season with a single dose
In two clinical trials, Evrysdi improved motor function in people living with SMA over a broad spectrum of ages and levels of disease severity, including Types 1, 2, and 3 SMA
The high-throughput system enables laboratories to double or even triple their testing capacity
The partnership enables LUMICKS to expand on the implementation of the z-Movi to new immunotherapeutic settings
The new reagent kits aim to make whole genome sequencing more accessible and affordable for labs of all sizes
This powerful new solution aims to provide more accurate COVID-19 antibody detection
